THNR Performance — Amplify Weight Loss Drug & Treatment ETF
Data updated: 2026-08-28
THNR returned +1.93% year to date and +15.20% over one year to Jun 2026. Over one year the fund trailed its Global Health Care Equity category average: $100 grew to $115, against $124 for the category. Volatility over the past 12 months was 14.44% a year. In the 12 months to Jun 2026 the fund took in a net $992K, and assets reached $4.36M.
THNR Growth of $100
What $100 invested in Amplify Weight Loss Drug & Treatment ETF grew to, compounded from monthly returns reported on SEC Form N-PORT, against the Global Health Care Equity category average over the same months.
| Period | THNR | Category average |
|---|---|---|
| 1 year (Jul 2025 – Jun 2026) | $115 | $124 |
| Since data start (Apr 2024 – Jun 2026) | $105 | $123 |
THNR Trailing Returns
Total returns to Jun 2026, from SEC N-PORT.
| Period | Total return |
|---|---|
| YTD | +1.93% |
| 1 year | +15.20% |
| 3 years (annualised) | +1.98% |
THNR Annual Returns
Calendar-year total returns of Amplify Weight Loss Drug & Treatment ETF, compounded from monthly SEC N-PORT returns. Partial years show the months covered.
| Year | Total return |
|---|---|
| 2026 (Jan–Jun) | +1.93% |
| 2025 | +13.26% |
| 2024 (Apr–Dec) | −9.47% |
THNR Monthly Returns
Monthly total returns as reported on SEC Form N-PORT.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | +4.0% | −0.8% | −5.9% | −0.1% | +2.1% | +3.0% | — | — | — | — | — | — |
| 2025 | +2.4% | +1.7% | −8.6% | +2.5% | +0.9% | +1.9% | −0.6% | +2.2% | +2.1% | −0.8% | +11.5% | −1.4% |
| 2024 | — | — | — | 0.0% | +0.2% | +2.9% | +1.3% | +6.9% | −5.0% | −5.6% | −5.1% | −4.7% |
THNR Risk
Risk measures from monthly returns over Jul 2025 – Jun 2026.
- 1-year volatility (annualised): 14.44%
- Best month: +11.52% (Nov 2025)
- Worst month: −5.95% (Mar 2026)
THNR Fund Flows
Monthly money in and out of Amplify Weight Loss Drug & Treatment ETF, from SEC Form N-PORT.
- 12-month net flow: $992K
- 12-month gross sales (incl. reinvestments): $2.7M
- Sales ÷ redemptions: 1.60×
| Month | Sales | Redemptions | Net flow |
|---|---|---|---|
| Jun 2026 | $0 | $0 | $0 |
| May 2026 | $0 | $0 | $0 |
| Apr 2026 | $0 | $0 | $0 |
| Mar 2026 | $0 | $0 | $0 |
| Feb 2026 | $519K | $0 | $519K |
| Jan 2026 | $1.0M | $0 | $1.0M |
| Dec 2025 | $0 | $0 | $0 |
| Nov 2025 | $0 | $0 | $0 |
| Oct 2025 | $0 | $493K | −$493K |
| Sep 2025 | $0 | $1.2M | −$1.2M |
| Aug 2025 | $1.1M | $0 | $1.1M |
| Jul 2025 | $0 | $0 | $0 |
THNR Assets Under Management
Net assets of Amplify Weight Loss Drug & Treatment ETF by report date, from SEC N-PORT filings.
| Report date | Net assets |
|---|---|
| 2026-06-30 | $4.36M |
| 2026-03-31 | $4.15M |
| 2025-12-31 | $2.77M |
| 2025-09-30 | $3.05M |
| 2025-06-30 | $2.94M |
| 2025-03-31 | $3.87M |
| 2024-12-31 | $4.07M |
| 2024-09-30 | $4.81M |
| 2024-06-30 | $3.12M |
For information only. Not investment advice: figures are as reported in SEC filings and may contain errors or be out of date. Past performance does not guarantee future results.